Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

Every Patient In This Bowel Cancer Trial Has Been Cancer Free For Nearly Three Years

In one of the most striking results from any cancer clinical trial in recent years, every single patient in a bowel cancer study has remained cancer-free for nearly three years after receiving a short course of immunotherapy before surgery, with zero relapses recorded in the entire cohort as of the latest follow-up data. The NEOPRISM-CRC trial, led by researchers at University College London and University College London Hospitals, gave patients with a specific form of stage two or three bowel cancer nine weeks of pre-operative treatment with the immunotherapy drug pembrolizumab, replacing the conventional approach of post-operative chemotherapy. Initial results showed that 59 percent of patients had no detectable cancer after the immunotherapy and surgery combined, and the new follow-up data at 33 months shows that not only have those patients remained clear, but even the patients who still had small amounts of cancer remaining after treatment saw none of it grow or spread. Under the standard treatment pathway, roughly 25 percent of similar patients would be expected to relapse within three years.

The results were presented at the American Association for Cancer Research Annual Meeting in April 2026 and have generated significant excitement among oncologists. The specific bowel cancer treated in the trial, known as mismatch repair-deficient cancer, affects roughly 15 percent of all bowel cancer patients and is characterized by genetic errors that make it particularly responsive to immunotherapy. Researchers noted that the results suggest a nine-week drug course could replace months of chemotherapy and provide more durable protection against recurrence, a potential shift in how this form of the disease is treated from the ground up. Scientists called the zero-relapse figure at nearly three years extraordinary, and said larger trials are now needed to confirm and extend the findings across wider patient populations.

Source: https://scitechdaily.com/breakthrough-bowel-cancer-trial-leaves-patients-cancer-free-for-nearly-3-years/

PrevPreviousColorado Just Banned Pet Store Dog And Cat Sales
NextA 12-Year-Old Fighting Brain Cancer Raised $22 At A Lemonade Stand For Research And Then Something Incredible HappenedNext

Recent Articles

Happy News

Eating Eggs Regularly May Cut Alzheimers Risk By Up To 27 Percent

May 9, 2026

A new study from Loma Linda University Health has found that adults 65 and older who eat eggs regularly have a significantly lower risk of developing Alzheimer’s disease, with people who consumed at least one egg per day for five or more days a week showing up to a 27

Read More
Happy News

Birdwatching Among Gen Z In Britain Has Grown By Over 1000 Percent Since 2018 And The Reasons Why Are Beautiful

May 8, 2026

Birdwatching has quietly become one of the fastest-growing hobbies among young people in Britain, with new research from the Royal Society for the Protection of Birds finding that nearly 750,000 people aged 16 to 29 now birdwatch regularly, a staggering increase of more than 1,000 percent since 2018. The study

Read More
Happy News

Meet The Record Holders Who Prove That Age Is Genuinely Just A Number

May 8, 2026

Guinness World Records has published a new feature celebrating some of the most extraordinary older athletes on the planet, a collection of record holders that makes a compelling case that age really is just a number. Leading the group is Mathea Allansmith of Hawaii, born in 1930, who took up

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.